Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib

키워드

참고문헌 (19)

1. Torre LA, "Global cancer statistics, 2012", CA Cancer J Clin, 65, pp.87~108 (2015)
2. Mok TS, "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361, pp.947~957 (2009)
3. Zhou C, "Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer(OPTIMAL, CTONG-0802) : a multicentre, open-label, randomised, phase 3 study", Lancet Oncol, 12, pp.735~742 (2011)
4. Li D, "BIBW2992, an irreversible EGFR", HER2inhibitor highly effective in preclinical lung cancer models, 2008, pp.27, 4702~4711
5. Sequist LV, "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations", J Clin Oncol, 31, pp.3327~3334 (2013)
6. Wu YL, "Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations(LUX-Lung 6) : an open-label, randomised phase 3 trial", Lancet Oncol, 15, pp.213~222 (2014)
7. Urata Y, "Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma : WJOG 5108L", J Clin Oncol, 34, pp.3248~3257 (2016)
8. Park K, "Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer(LUXLung 7) : a phase 2B, open-label, randomised controlled trial", Lancet Oncol, 17, pp.577~589 (2016)
9. Chen KL, "Comparison of skin toxic effects associated with gefitinib, erlotinib, or afatinib treatment for non-small cell lung cancer", JAMA Dermatol, 152, pp.340~342 (2016)
10. Yang JC, "Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma(LUX-Lung 3and LUX-Lung 6) : analysis of overall survival data from two randomised, phase 3 trials", Lancet Oncol, 16, pp.141~151 (2015)
11. Mok T, "Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): a randomized, open-label phase III trial", J Clin Oncol, 35(Suppl), pp.LBA9007~ (2017)
12. Jackman DM, "Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib", Clin Cancer Res, 12, pp.3908~3914 (2006)
13. Lynch TJ, "Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib", N Engl J Med, 350, pp.2129~2139 (2004)
14. Paez JG, "EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy", Science, 304, pp.1497~1500 (2004)
15. Wu JY, "Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer", Onco Targets Ther, 9, pp.6137~6145 (2016)
16. Baek JH, "Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFRmutated non-small cell lung cancer except both exon 19deletion and exon 21 L858R : a retrospective analysis in Korea", Lung Cancer, 87, pp.148~154 (2015)
17. Shen YC, "Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations", Lung Cancer, 110, pp.56~62 (2017)
18. Yang JC, "Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: findings from three trials of afatinib in Egfr mutation-positive lung cancer", J Thorac Oncol, 8(Suppl 2), pp.S141~ (2013)
19. Liu CY, "The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib(Giotrif)as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations", Oncotarget, 8, pp.97602~97612 (2017)

관련 논문AI추천